Physician profile
Adam Robert Klang
NPI 1386732246
$1,495.61
in general payments reported to CMS, 2019-2025
17 companies · $117 in 2025
The $117 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $470 · 2020: $266 · 2021: $213 · 2022: $127 · 2023: $75.43 · 2024: $228 · 2025: $117.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $420.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $420.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $436.22 | 2019-2021 | |
| Janssen Pharmaceuticals, INC | $316.73 | 2019-2022 | |
| Novo Nordisk INC | $139.77 | 2024-2025 | Ozempic, Rybelsus, Wegovy |
| Teva Pharmaceuticals USA, INC. | $120.30 | 2024-2025 | Uzedy |
| Astellas Pharma US INC | $116.23 | 2020 | |
| Dexcom, INC. | $65.07 | 2024 | Dexcom G7 Gss (161), Dexcom G6 Transmitter |
| Collegium Pharmaceutical, INC. | $54.41 | 2022 | |
| Glaxosmithkline, LLC. | $46.94 | 2023 | Trelegy Ellipta |
| E.R. Squibb & Sons, L.L.C. | $38.53 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $32.67 | 2019-2021 | |
| Advanced Respiratory, INC | $30.25 | 2019 | |
| Abbott Laboratories | $22.19 | 2021 | |
| Lilly USA, LLC | $19.43 | 2025 | Zepbound, Mounjaro |
| Lundbeck LLC | $15.42 | 2023 | Abilify Asimtufii |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.70 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $13.68 | 2022 | |
| Nestle Healthcare Nutrition INC. | $13.07 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Adam Klang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.